Investigational Drug Details
| Drug ID: | D092 |
| Drug Name: | Curcumin |
| Synonyms: | Turmeric |
| Type: | Chemical drug |
| DrugBank ID: | DB11672 |
| DrugBank Description: | Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in . It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell Lung Cancer (NSCLC). Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin . Curcumin is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment (MCI) . |
| PubChem ID: | 969516 |
| CasNo: | 458-37-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(=C\C(=O)CC(=O)/C=C/c1cc(OC)c(cc1)O)/c1cc(OC)c(cc1)O |
| Structure: |
|
| InChiKey: | VFLDPWHFBUODDF-FCXRPNKRSA-N |
| Molecular Weight: | 368.385 |
| DrugBank Targets: | Peroxisome proliferator-activated receptor gamma; Vitamin D3 receptor; Multidrug resistance-associated protein 5 inhibitor; Carbonyl reductase [NADPH] 1; Glutathione S-transferase P |
| DrugBank MoA: | Curcumin acts as a scavenger of oxygen species, such as hydroxyl radical, superoxide anion, and singlet oxygen and inhibit lipid peroxidation as well as peroxide-induced DNA damage . Curcumin mediates potent anti-inflammatory agent and anti-carcinogenic actions via modulating various signalling molecules. It suppresses a number of key elements in cellular signal transduction pathways pertinent to growth, differentiation, and malignant transformation; it was demonstrated _in vitro_ that curcumin inhibits protein kinases, c-Jun/AP-1 activation, prostaglandin biosynthesis, and the activity and expression of the enzyme cyclooxygenase (COX)-2 . |
| DrugBank Pharmacology: | Intravenous application of 25 mg/kg bw curcumin to rats resulted in an increase in bile flow by 80 and 120% . In the rat model of inflammation, curcumin was shown to inhibit edema formation. In nude mouse that had been injected subcutaneously with prostate cancer cells, administration of curcumin caused a marked decrease in the extent of cell proliferation, a significant increase of apoptosis and micro-vessel density . Curcumin may exert choleretic effects by increasing biliary excretion of bile salts, cholesterol, and bilirubin, as well as increasing bile solubility . Curcumin inhibited arachidonic acid-induced platelet aggregation _in vitro_ . |
| DrugBank Indication: | No approved therapeutic indications. |
| Targets: | PPARG; COX inhibitor |
| Therapeutic Category: | Anticancer agent; NSAID |
| Clinical Trial Progress: | Phase 2 on-going (NCT04315350) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0033 | NCT04109742 | Phase 2 | Withdrawn | No Results Available | December 9, 2019 | September 27, 2021 | Details |
| L0136 | NCT04315350 | Not applicable | Recruiting | No Results Available | December 1, 2019 | October 8, 2021 | Details |
| L0381 | IRCT20170628034786N4 | Phase 3 | Not Recruiting | No Results Available | 04/07/2021 | 12 July 2021 | Details |
| L0429 | IRCT20121216011763N47 | Not applicable | Not Recruiting | No Results Available | 14/05/2020 | 15 June 2020 | Details |
| L0443 | IRCT20121216011763N42 | Not applicable | Recruiting | No Results Available | 10/01/2020 | 24 February 2020 | Details |
| L0458 | IRCT20190602043787N1 | Phase 2/Phase 3 | Recruiting | No Results Available | 09/08/2019 | 7 October 2019 | Details |
| L0499 | IRCT20100524004010N24 | Not applicable | Not Recruiting | No Results Available | 14/05/2018 | 18 June 2018 | Details |
| L0530 | IRCT2014110511763N18 | Not applicable | Not Recruiting | No Results Available | 18/01/2015 | 22 February 2018 | Details |
| L0544 | IRCT2017012031423N1 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 22/05/2017 | 22 February 2018 | Details |
| L0551 | IRCT201702209662N12 | Phase 1/Phase 2 | Not Recruiting | No Results Available | 25/04/2017 | 22 February 2018 | Details |
| L0570 | IRCT2015052322381N1 | Phase 3 | Not Recruiting | No Results Available | 17/09/2016 | 5 November 2019 | Details |
| L0574 | IRCT2016071915536N3 | Not applicable | Not Recruiting | No Results Available | 02/08/2016 | 22 February 2018 | Details |
| L0631 | TCTR20140303003 | Phase 3 | Not Recruiting | No Results Available | 03/03/2014 | 7 February 2022 | Details |
| L0661 | JPRN-UMIN000007015 | Not selected | Not Recruiting | No Results Available | 04/01/2012 | 2 April 2019 | Details |
| L0713 | IRCT20190103042219N1 | Not applicable | Not Recruiting | No Results Available | 14/12/2019 | 17 December 2019 | Details |
| L0718 | IRCT20121216011763N39 | Not applicable | Not Recruiting | No Results Available | 26/11/2019 | 17 December 2019 | Details |
| L0764 | NCT03864783 | Not applicable | Not recruiting | No Results Available | 26/02/2019 | 16 February 2021 | Details |
| L0781 | JPRN-UMIN000033774 | Not selected | Not Recruiting | No Results Available | 22/11/2018 | 2 April 2019 | Details |
| L0841 | NCT02908152 | Phase 2/Phase 3 | Not recruiting | No Results Available | 05/09/2016 | 12 December 2020 | Details |
| L0854 | IRCT2015122525641N2 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 16/01/2016 | 22 February 2018 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00373 | 35113098 | Food Funct | Curcumin alleviates hepatic steatosis by improving mitochondrial function in postnatal overfed rats and fatty L02 cells through the SIRT3 pathway. | Details |
| A00744 | 34981470 | Adv Exp Med Biol | The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review. | Details |
| A00745 | 34981468 | Adv Exp Med Biol | Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial. | Details |
| A00803 | 34959992 | Nutrients | Curcumin in Metabolic Health and Disease. | Details |
| A00850 | 34948230 | Int J Mol Sci | It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | Details |
| A01006 | 34904613 | Food Funct | Steatosis induced by nonylphenol in HepG2 cells and the intervention effect of curcumin. | Details |
| A01167 | 34847213 | Food Funct | Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence. | Details |
| A01663 | 34663438 | Diabetol Metab Syndr | The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial. | Details |
| A01837 | 34599938 | Life Sci | Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). | Details |
| A02260 | 34444811 | Nutrients | Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)-A Review. | Details |
| A02278 | 34439562 | Antioxidants (Basel) | Curcumin Suppresses the Lipid Accumulation and Oxidative Stress Induced by Benzo[a]pyrene Toxicity in HepG2 Cells. | Details |
| A02279 | 34439491 | Antioxidants (Basel) | TRPM2 Non-Selective Cation Channels in Liver Injury Mediated by Reactive Oxygen Species. | Details |
| A02506 | 34348707 | J Nanobiotechnology | Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. | Details |
| A02582 | 34323067 | J Agric Food Chem | Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. | Details |
| A03460 | 33992930 | Eur J Med Chem | Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. | Details |
| A03796 | 33861449 | Adv Exp Med Biol | Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. | Details |
| A03797 | 33861444 | Adv Exp Med Biol | Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review. | Details |
| A03798 | 33861434 | Adv Exp Med Biol | The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. | Details |
| A03915 | 33820503 | Mini Rev Med Chem | Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. | Details |
| A03970 | 33805912 | Int J Mol Sci | Potential of Nutraceutical Supplementation in the Modulation of White and Brown Fat Tissues in Obesity-Associated Disorders: Role of Inflammatory Signalling. | Details |